Literature DB >> 21132452

Successful surgical treatment and chemotherapy for ovarian cancer in a patient with idiopathic thrombocytopenic purpura.

Kimio Wakana1, Toshiharu Yasugi, Yurie Nako, Tomomi Nei, Yoshikazu Ozaki, Katsumi Mizutani.   

Abstract

Ovarian clear cell adenocarcinoma (OCCA) is known to have a worse prognosis than ovarian serous adenocarcinoma due to its poor response to conventional platinum-based chemotherapy. Idiopathic thrombocytopenic purpura (ITP), which usually reveals severe thrombocytopenia, is a common autoimmune disorder. However, to date very few cases of ovarian cancer associated with ITP have been reported in the literature. We report a case of a 57-year-old woman who developed OCCA 14 years after the diagnosis of ITP. The patient presented with abdominal distention and mild tenderness. We performed the operation with high-dose immunoglobulin therapy preoperatively, and diagnosed OCCA. Postoperatively, six cycles of cytotoxic chemotherapy with irinotecan hydrochloride plus cisplatin were performed every 4-5 weeks without thrombocytopenia. We conclude that combination chemotherapy with irinotecan hydrochloride plus cisplatin is useful for a case of OCCA associated with ITP.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21132452     DOI: 10.1007/s10147-010-0149-3

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  8 in total

1.  Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone.

Authors:  Yunfeng Cheng; Raymond S M Wong; Yannie O Y Soo; Chung Hin Chui; Fung Yi Lau; Natalie P H Chan; Wai Shan Wong; Gregory Cheng
Journal:  N Engl J Med       Date:  2003-08-28       Impact factor: 91.245

Review 2.  Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology.

Authors:  J N George; S H Woolf; G E Raskob; J S Wasser; L M Aledort; P J Ballem; V S Blanchette; J B Bussel; D B Cines; J G Kelton; A E Lichtin; R McMillan; J A Okerbloom; D H Regan; I Warrier
Journal:  Blood       Date:  1996-07-01       Impact factor: 22.113

3.  Idiopathic thrombocytopenic purpura and ovarian cancer.

Authors:  A Chehal; A Taher; M Seoud; A Shamseddine
Journal:  Eur J Gynaecol Oncol       Date:  2003       Impact factor: 0.196

4.  Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.

Authors:  Robert F Ozols; Brian N Bundy; Benjamin E Greer; Jeffrey M Fowler; Daniel Clarke-Pearson; Robert A Burger; Robert S Mannel; Koen DeGeest; Ellen M Hartenbach; Rebecca Baergen
Journal:  J Clin Oncol       Date:  2003-07-14       Impact factor: 44.544

Review 5.  Recurrent ovarian carcinoma: presentation as idiopathic thrombocytopenic purpura and a splenic mass.

Authors:  H M Tarraza; R Carroll; M De Cain; M Jones
Journal:  Eur J Gynaecol Oncol       Date:  1991       Impact factor: 0.196

6.  Breast cancer associated with idiopathic thrombocytopenic purpura: a single center series of 10 cases.

Authors:  Régis Peffault de Latour; Gaëtan Des Guetz; Valérie Laurence; Thao Palangié; Jean-Yves Pierga; Véronique Diéras; Michel Jouve; Jean-Marc Extra; Pierre Pouillart; Didier Decaudin
Journal:  Am J Clin Oncol       Date:  2004-08       Impact factor: 2.339

7.  Irinotecan (CPT-11) and cisplatin as first-line chemotherapy for advanced ovarian cancer.

Authors:  Toru Sugiyama; Michiaki Yakushiji; Toshiharu Kamura; Masanori Ikeda; Naohiko Umesaki; Kazuo Hasegawa; Mutsuo Ishikawa; Fumitaka Saji; Masamichi Hiura; Takeshi Takahashi; Shinji Sato; Kazunori Ochiai; Fumitaka Kikkawa; Shoshichi Takeuchi; Yasuo Ohashi; Kiichiro Noda
Journal:  Oncology       Date:  2002       Impact factor: 2.935

8.  Randomized phase II trial of paclitaxel plus carboplatin therapy versus irinotecan plus cisplatin therapy as first-line chemotherapy for clear cell adenocarcinoma of the ovary: a JGOG study.

Authors:  Satoshi Takakura; Masashi Takano; Fumiaki Takahashi; Toshiaki Saito; Daisuke Aoki; Noriyuki Inaba; Kiichiro Noda; Toru Sugiyama; Kazunori Ochiai
Journal:  Int J Gynecol Cancer       Date:  2010-02       Impact factor: 3.437

  8 in total
  1 in total

1.  Combined subtotal gastrectomy and splenectomy after partial splenic embolization for a patient with gastric cancer and immune thrombocytopenic purpura: A case report.

Authors:  Yuki Kaneko; Shin Saito; Daijiro Takahashi; Takashi Ui; Hidenori Haruta; Kentaro Kurashina; Hironori Yamaguchi; Yoshinori Hosoya; Joji Kitayama; Alan Kawarai Lefor; Naohiro Sata
Journal:  Int J Surg Case Rep       Date:  2019-08-31
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.